Cilengitide in Patients with Recurrent Glioblastoma: The Results of NABTC 03-02, a Phase II Trial with Measures of Treatment Delivery

PURPOSE: Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the αvβ3 and αvβ5 integrins. Preclinical studies demonstrate antiangiogenic activity and anti-invasive activity in a number of glioma models. This study was designed to evaluate the efficacy and tumor delivery of cilengiti...

Full description

Saved in:
Bibliographic Details
Published in:J Neurooncol
Main Authors: Gilbert, Mark R., Kuhn, John, Lamborn, Kathleen R., Lieberman, Frank, Wen, Patrick Y., Mehta, Minesh, Cloughesy, Timothy, Lassman, Andrew B., DeAngelis, Lisa M., Chang, Susan, Prados, Michael
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351869/
https://ncbi.nlm.nih.gov/pubmed/21739168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0650-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items